Status:
COMPLETED
Evaluation of Vitrase as a Spreading Agent
Lead Sponsor:
Bausch & Lomb Incorporated
Conditions:
Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether Vitrase (hyaluronidase for injection) is effective as a spreading agent for other injected drugs prior to ocular surgery
Eligibility Criteria
Inclusion
- Scheduled for an ophthalmic surgical procedure
Exclusion
- Documented history of hypersensitivity to hyaluronidase or any other ingredient in Vitrase
- Known history of hypersensitivity reaction to bee or wasp venom
- Needing enhanced absorption and dispersion of dopamine, alpha agonist drugs, furosemide, the benzodiazepines, or phenytoin
- Inflammation or apparent clinical signs of infection in the area where Vitrase was to be injected
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2005
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT00198484
Start Date
October 1 2004
End Date
February 1 2005
Last Update
March 14 2013
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
David Wirta, MD, Inc.
Newport Beach, California, United States, 92663
2
Richard A Lewis, MD
Sacramento, California, United States, 95815
3
E Randy Craven, MD
Littleton, Colorado, United States, 80120
4
The Eye Care Group
New Haven, Connecticut, United States, 06510